Literature DB >> 26134177

The Post-Anesthetic Care of Pediatric Patients With Pulmonary Hypertension.

Destiny F Chau1, Meera Gangadharan2, Lopa P Hartke3, Mark D Twite4.   

Abstract

Few conditions make even the most experienced pediatric anesthesiologists take pause. Pulmonary hypertension is one such condition due to the associated high perioperative morbidity and mortality. Much is written about the intraoperative management of pediatric pulmonary hypertension. This article will instead focus on postoperative care and review the evidence in support of a risk stratification approach for the post-anesthetic disposition of these patients. The total risk for post-anesthetic adverse events includes the patient's baseline risk factors and the incremental risks imposed by the procedure and anesthetic. A proposal with recommendations to guide practitioners and a table summarizing relevant factors are provided. Last, the readers' attention is drawn to the heterogeneity of pulmonary hypertensive disease. Pulmonary arterial hypertension (precapillary) differs significantly from pulmonary venous hypertension (postcapillary); the anesthetic management for one may be relatively contraindicated in the other. Their dissimilarities justify the need to distinguish them for study and research endeavors.
© The Author(s) 2015.

Entities:  

Keywords:  cardiac anesthesia; children; hypertension; pediatric intensive care; perioperative mortality; postoperative care; postoperative complications; pulmonary artery pressure

Mesh:

Year:  2015        PMID: 26134177     DOI: 10.1177/1089253215593179

Source DB:  PubMed          Journal:  Semin Cardiothorac Vasc Anesth        ISSN: 1089-2532


  1 in total

1.  Prevalence of elevated right ventricular pressure in children with obstructive sleep apnea syndrome undergoing pulmonary hypertension screening.

Authors:  Anna C Bitners; Raanan Arens; Joseph Mahgerefteh; Nicole J Sutton; Ellen J Silver; Sanghun Sin; Masrur A Khan; Christina J Yang
Journal:  J Clin Sleep Med       Date:  2021-11-01       Impact factor: 4.062

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.